Introduction
InterMune is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The company markets Actimmune (interferon gamma-1b), approved for the treatment of severe, malignant osteopetrosis and chronic granulomatous disease. The company acquired core patents for pirfenidone from Marnac and KDL in November 2007.
Scope
Contains corporate strategy, value chain presence and SWOT Analysis Provides detailed business description, segment analysis, 5-year financial trends, key products and key competitors Includes information on suppliers/ partners, shareholding structure and key employees with biographies
Highlights
InterMune has a late-stage and preclinical development pipeline in the areas of pulmonology and hepatology. In pulmonology, the company is developing two therapies for the treatment of idiopathic pulmonary fibrosis (IPF): interferon gamma-1b and pirfenidone and in hepatology, it is expanding options for patients suffering from HCV infections Historically, the company derived majority of its revenues during 2002-2006 from product sales of Actimmune, Infergen, Amphotec and Oritavancin. The company's total revenues decreased at a CAGR of -5% during 2002-2006, from $112 million to $91 million, representing an absolute decline of -$21 million for the same period. InterMune's biggest contributor to sales growth out to 2010 will be revenues from Pirfenidone sales. Revenues from Pirfenidone are expected to contribute $111 million in 2010, representing an absolute growth of +$111 million for the period 2006-2010.
Reasons to Purchase
Access all the important information and analysis on the company in a single report Understand company's strengths, weaknesses, opportunities and threats along with business strategy and value chain Gain access to company's adjusted five year financial data along with key ratios and market capitalization.
Report Highlights
[Studien Infos ausblenden]
